Stephen Tullman, Chairman of the Board and Chief Executive Officer

Joining Ceptaris in May 2011, Mr. Tullman brings more than 21 years of biopharmaceutical global commercialization and drug development experience. Mr. Tullman formerly served as the Executive Chairman of Vicept Therapeutics, which was acquired by Allergan Therapeutics in July 2011, and has co-founded and led numerous companies: Ception Therapeutics, a biologics company (acquired by Cephalon); Trigenesis Therapeutics, a dermatology company (acquired by Dr. Reddy’s Laboratories); and Cutix Pharmaceuticals, a privately held dermatology company. He also served on the Board of Directors for Euromed, a wound care company. Mr. Tullman started his career at GlaxoSmithKline and held positions of increasing responsibility in finance, sales, marketing, and research and development. Mr. Tullman earned a B.S. from Rutgers University in New Jersey.

Albert Cha, M.D., Ph.D., Managing Partner, Vivo Ventures

As managing partner of Vivo Ventures, Dr. Albert Cha invests in private and public biopharmaceutical and medical device companies. He currently serves on the board of several private biopharmaceutical and medical device companies and has also served as co-founder of several portfolio companies. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. He completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience. During his studies, he was elected to Alpha Omega Alpha and won the prestigious Outstanding Graduate Student Award. He earned his B.S. and M.S. in Electrical Engineering from Stanford University.

John Doux, M.D., Analyst, Palo Alto Investors

John Doux has been an analyst at Palo Alto Investors since 2004. He obtained a B.S. with distinction and an M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He also completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice.

David Drahms, Principal, Osage Ventures

David began his career at Teradyne, Inc., a Boston-based manufacturer of semiconductor test equipment, where he was a mechanical engineer before becoming a project manager. He then attended The Wharton School, where he graduated with an M.B.A. in Entrepreneurship. While at Wharton, Mr. Drahms spent the summer as an internal strategist with Rohm and Haas, traveled to Peru to advise a consumer textiles company on a U.S. market entry strategy, and consulted with Teach for America on how to optimize their recruitment process. Mr. Drahms serves on the Board of Directors for Red Lasso and is a Board Observer for Melior Discovery and HardMetrics.

william Hamilton, Ph.D., Ralph Landau Professor of Management and Technology,
University of Pennsylvania

Dr. Hamilton has served on the University of Pennsylvania faculty since 1967. He is the Ralph Landau Professor of Management and Technology and Director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. He also serves as a Director of Arno Therapeutics, Inc., a life sciences company. He previously served as a Director of Avid Radiopharmaceuticals, Inc. prior to its acquisition by Eli Lilly and Centocor, Inc. prior to its acquisition by Johnson & Johnson. Dr. Hamilton earned his Ph.D. in Applied Economics from the London School of Economics, and received his M.B.A. and a M.S. and B.S. in Chemical Engineering from the University of Pennsylvania.